Cargando…
Targeting Orphan G Protein-Coupled Receptor 17 with T0 Ligand Impairs Glioblastoma Growth
SIMPLE SUMMARY: Glioblastoma multiforme (GBM), or glioblastoma chemotherapy, has one of the poorest improvements across all types of cancers. Despite the different rationales explored in targeted therapy for taming the GBM aggressiveness, its phenotypic plasticity, drug toxicity, and adaptive resist...
Autores principales: | Doan, Phuong, Nguyen, Phung, Murugesan, Akshaya, Subramanian, Kumar, Konda Mani, Saravanan, Kalimuthu, Vignesh, Abraham, Bobin George, Stringer, Brett W., Balamuthu, Kadalmani, Yli-Harja, Olli, Kandhavelu, Meenakshisundaram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345100/ https://www.ncbi.nlm.nih.gov/pubmed/34359676 http://dx.doi.org/10.3390/cancers13153773 |
Ejemplares similares
-
Synthesis and Preclinical
Validation of Novel Indole
Derivatives as a GPR17 Agonist for Glioblastoma Treatment
por: Nguyen, Phung, et al.
Publicado: (2021) -
Identifying the miRNA Signature Association with Aging-Related Senescence in Glioblastoma
por: Gnanavel, Mutharasu, et al.
Publicado: (2021) -
Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity
por: Doan, Phuong, et al.
Publicado: (2021) -
Synthesis and preclinical validation of novel P2Y1 receptor ligands as a potent anti-prostate cancer agent
por: Le, Hien Thi Thu, et al.
Publicado: (2019) -
Anticancer activity of THMPP: Downregulation of PI3K/ S6K1 in breast cancer cell line
por: Palanivel, Suresh, et al.
Publicado: (2020)